您的位置:网站名称 研发专利新闻 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

USPTO issues patent to Oragenics ProBiora3 for oral care


Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) (www.oragenics.com) announced today the issuance of patent number 7931892 from the United States Patent and Trademark office for ProBiora3®, a proprietary blend of naturally occurring oral bacteria shown to produce a wide range of oral care benefits. ProBiora3 contains three strains of beneficial oral bacteria that help maintain a healthy microbial balance in the mouth. It is 100% natural and is made in the USA in an FDA-registered and GMP-certified facility.

Issuance of the patent enables Oragenics to immediately pursue global private label and licensing opportunities in major product categories such as food and beverage, health and wellness, pet care and nutrition. The market size of these channels collectively exceeds $170 billion. Product suppliers in these categories, ranging from those with well established brands to newer market entrants, will be able to achieve newfound product differentiation with ProBiora3, as its beneficial characteristics provide a meaningful value added benefit to consumers.

ProBiora3 technology was developed by Oragenics' Chief Scientific Officer Dr. Jeffrey Hillman D.M.D., Ph.D., during more than 25 year of research, which began at the Harvard affiliated Forsyth Institute in Boston and was fully developed at Oragenics. This technology is currently available in Oragenics' line of probiotic products for oral care for the entire family including EvoraPro®, EvoraPlus®, EvoraKids®, EvoraPet™ and Teddy's Pride™.

"The concept behind ProBiora3 takes advantage of the observation that not all bacteria are bad," said Dr. Hillman. "In a complex environment like the mouth, we predicted that we would find certain types of bacteria that are associated with healthy teeth and gums. Finding these bacteria and using them to create ProBiora3 is the first of several innovative technologies discovered from oral biology, which Oragenics plans to bring to the marketplace."

Probiora3 has the potential to be a beneficial ingredient for a wide range of product categories and applications. Oral care products such as toothpaste, rinses and floss are obvious examples, but many products that are consumed orally have the potential to deliver the benefits of ProBiora3 to consumers. The emerging functional foods and beverage category provides a significant opportunity for the integration of ProBiora3. Consumers of yogurt, for instance, are aware of the beneficial effects of probiotics for digestion and immune health. New opportunities in wellness categories such as nutritional supplements, where consumers are receptive to products containing new ingredients (particularly those that are science-based, such as ProBiora3), present potential partnerships with recognized brands globally.

ProBiora3 also has the potential to have a major impact on the pet care industry. Oral care issues such as bad breath and stained teeth are among the most prevalent problems pet owners face. ProBiora3 addresses these issues and can be used as an ingredient in foods, treats and products with diverse delivery systems.

查看所有的文章内容需要 VIP会员权限 查看


 
点这里复制本页地址发送给您QQ/MSN上的好友

相关文章

WSU researcher develops potential vaccin
Watson Laboratories seeks FDA approval t
Salix Pharmaceuticals receives three U.S
Acorda receives patent for AMPYRA tablet
U.S. District Court grants preliminary i
QRxPharma receives new U.S. Patent for M
EPO grants patent to OncoGenex OGX-427 f
Echo awarded method patent for Symphony
USPTO issues new patent to Onset Medical
Watson confirms patent challenge by Alco
POZEN, AstraZeneca file lawsuit against
Pro-Pharmaceuticals receives method pate
NovaSterilis novel vaccine patent
USPTO grants Cortex patent for CX1739 AM
EPO grants patent to Microbix' VIRUSMAX
MSF letter criticizes Johnson & Johnson

相关评论


本文章所属分类:首页 研发专利新闻